Overview

Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The investigators reasoned that a hypertonic saline concentration higher than 3% could be safe and more efficacious in the treatment of bronchiolitis, alleviating severe symptoms and preventing the need for hospitalization in some instances.
Phase:
Phase 4
Details
Lead Sponsor:
Hamad Medical Corporation
Treatments:
Epinephrine
Epinephryl borate
Racepinephrine